Prospective participant selection and ranking to maximize actionable pharmacogenetic variants and discovery in the eMERGE Network

Genome Medicine

Volumn 7, Issue 1, 2015, Pages

  Crosslin, David R ^a,b   Robertson, Peggy D ^b   Carrell, David S ^c   Gordon, Adam S ^b   Hanna, David S ^b   Burt, Amber ^a   Fullerton, Stephanie M ^a   Scrol, Aaron ^c   Ralston, James ^b   Leppig, Kathleen ^b   Hartzler, Andrea ^b   Baldwin, Eric ^b   Andrade, Mariza de ^d   Kullo, Iftikhar J ^d   Tromp, Gerard ^e   Doheny, Kimberly F ^f   Ritchie, Marylyn D ^g,h   Crane, Paul K ^a   Nickerson, Deborah A ^b   Larson, Eric B ^c   Jarvik, Gail P ^a,b   more..

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c CENTER FOR HEALTH STUDIES   (United States)

^d MAYO CLINIC   (United States)

^e WEIS CENTER FOR RESEARCH   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g PENNSYLVANIA STATE UNIVERSITY   (United States)

^h GEISINGER HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR; RYANODINE RECEPTOR 1; RYANODINE RECEPTOR 2; SODIUM CHANNEL NAV1.5;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; CACNA1S GENE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION SUPPORT SYSTEM; ELECTRONIC MEDICAL RECORD; ETHNIC DIFFERENCE; FEMALE; GAIN OF FUNCTION MUTATION; GENE; GENE IDENTIFICATION; GENETIC ALGORITHM; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; KCNH2 GENE; LDLR GENE; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; PATHOGENICITY; PATIENT SELECTION; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPIC VARIATION; PRIORITY JOURNAL; RYR1 GENE; RYR2 GENE; SCN5A GENE; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84938216839     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/s13073-015-0181-z     Document Type: Article

References (20)

1. Whirl-Carrillo M, McDonagh E, Hebert J, Gong L, Sangkuhl K, Thorn C, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012; 92:414-7. doi:10.1038/clpt.2012.96.
2. Relling M, Klein T. Cpic: Clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther. 2011; 89:464-7. doi:10.1038/clpt.2010.279.
3. Gordon A, Smith J, Metzker ML, ER M, Nickerson DA, Fulton R, et al.Pgrnseq: A targeted capture sequencing panel for pharmacogenetic research and implementation. Pharmacogenetics and Genomics in press. 2015.
4. Caudle KE, Klein TE, Hoffman JM, Müller DJ, Whirl-Carrillo M, Gong L, et al. Incorporation of pharmacogenomics into routine clinical practice: the clinical pharmacogenetics implementation consortium (cpic) guideline development process. Curr Drug Metab. 2014; 15:209-17. doi:10.2174/1389200215666140130124910.
5. Gottesman O, Kuivaniemi H, Tromp G, Faucett WA, Li R, Manolio TA, et al. The electronic medical records and genomics (emerge) network: past, present, and future. Genet Med. 2013; 15:761-71.
6. McCarty CA, Chisholm RL, Chute CG, Kullo IJ, Jarvik GP, Larson EB, et al. The emerge network: A consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med Genomics. 2011; 4:13-13. doi:10.1186/1755-8794-4-13.
7. Clinical Laboratory Improvement Amendments; Refining the structure and content of clinical genomic reports. Centers for Medicare & Medicaid Services ((Section 42 CFR §493.1291)).
8. Rasmussen-Torvik LJ, Stallings SC, Gordon AS, Almoguera B, Basford MA, Bielinski SJ, et al. Design and anticipated outcomes of the emerge-pgx project: A multicenter pilot for preemptive pharmacogenomics in electronic health record systems. Clin Pharmacol Ther. 2014; 96:482-9. doi:10.1038/clpt.2014.137.
9. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation discovery and genotyping using next-generation dna sequencing data. Nat Genet. 2011; 43:491-8.
10. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The genome analysis toolkit: A mapreduce framework for analyzing next-generation dna sequencing data. Genome Res. 2010; 20:1297-1303. doi:10.1101/gr.107524.110.
11. Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, del Angel G, Levy-Moonshine A, et al. From FastQ Data to High-Confidence Variant Calls: The Genome Analysis Toolkit Best Practices Pipeline: John Wiley & Sons, Inc.; 2002. doi:10.1002/0471250953.bi1110s43.
12. Cingolani P, Platts A, Wang LL, Coon M, Nguyen T, Wang L, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, snpeff: Snps in the genome of drosophila melanogaster strain w(1118); iso-2; iso-3. Fly. 2012; 6:80-92. doi:10.4161/fly.19695.
13. Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, et al. Clinvar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 2014; 42:980-5. doi:10.1093/nar/gkt1113.
14. Online Mendelian Inheritance in Man, OMIM®;. Johns Hopkins University: McKusick-Nathans Institute of Genetic Medicine; 2014.
15. Stenson PD, Mort M, Ball EV, Howells K, Phillips AD, Thomas NS, et al. The human gene mutation database: 2008 update. Genome Med. 2009; 1:13-13. doi:10.1186/gm13.
16. IUPAC-IUB Joint Commission on Biochemical Nomenclature Abbreviations and Symbols for the Description of Conformations of Polynucleotide Chains: John Wiley & Sons, Inc; 2001. doi:10.1002/0471142700.nca01cs00.
17. Eichelbaum M. Drug metabolism in thyroid disease. 1976; 1:339-50. doi:10.2165/00003088-197601050-00002.
18. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014; 46:310-5.
19. Cooper GM, Stone EA, Asimenos G, Branch NCSPGT, NHGRI NISCN, Green ED, et al. Distribution and intensity of constraint in mammalian genomic sequence. Genome Res. 2005; 15:901-13. doi:10.1101/gr.3577405.
20. Dorschner MO, Amendola LM, Shirts BH, Kiedrowski L, Salama J, Gordon AS, et al. Refining the structure and content of clinical genomic reports. Am J Med Genet Part C: Sem Med Genet. 2014; 166:85-92. doi:10.1002/ajmg.c.31395.